ChromaDex (CDXC) – Press Releases
-
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
-
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
-
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
-
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
-
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
-
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
-
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With
-
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movemen
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
-
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
-
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available,
-
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
-
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
-
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and
-
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Ade
-
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
-
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
-
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
-
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promisin
-
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program A
-
ChromaDex to Participate in the LD Micro Invitational XIII
-
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
-
ChromaDex Corporation Reports First Quarter 2023 Financial Results
-
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
-
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
-
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
-
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
-
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine
-
A Letter from the ChromaDex Chief Executive Officer
-
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD
-
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
-
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
-
ChromaDex Named Brianna Gerber Chief Financial Officer
-
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Po
-
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
-
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
-
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
-
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
-
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
-
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
-
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
-
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
-
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
-
Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer
-
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
-
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
-
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
-
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
Back to CDXC Stock Lookup
